Format

Send to

Choose Destination
J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Author information

1
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, 5150 Centre Avenue, Suite 564, Pittsburg, PA 15232 USA.
2
Hematopoietic Cellular Therapy Program, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637 USA.
3
Indiana University School of Medicine, 980 W. Walnut St., Walther Hall-R3, C400, Indianapolis, IN 46202 USA.
4
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 USA.
5
Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA.
6
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215 USA.
7
Smilow Cancer Hospital at Yale New Haven, 35 Park Street, New Haven, CT 06519 USA.
8
National Institutes of Health, Building 10-CRC Room 3-5330, Bethesda, MD 20814 USA.
9
Weill Cornell Medical College, 407 E 71st St, New York, NY 10065 USA.
10
Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259 USA.
11
Johns Hopkins School of Medicine, 1650 Orleans St, Baltimore, MD 21231 USA.
12
Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029 USA.
13
University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232 USA.
14
New York Medical College at Maria Fareri Children's Hospital, 100 Woods Road, Valhalla, New York 10595 USA.
15
Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104 USA.
16
MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.
17
City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 USA.
18
Wilmot Cancer Institute, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642 USA.
19
Johns Hopkins University School of Medicine, 401 N. Broadway, Baltimore, MD 21231 USA.
20
Yale Cancer Center, 333 Cedar Street, New Haven, CT 06511 USA.
21
Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110 USA.
22
The University of Chicago, 5841 S. Maryland Ave, Chicago, IL 60637 USA.
23
National Institutes of Health, National Cancer Institute, 8500 Roseweood Drive, Bethesda, MD 20814 USA.
24
City of Hope National Medical Center, 1500 E. Duarte Road, Beckman Bldg., Room 4117, Duarte, CA 91010 USA.
25
Division of Medical Oncology, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305 USA.
26
Department of Medicine-Hematology and Oncology, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH 44106 USA.
27
Department of Hematology, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905 USA.
28
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Box 0324, San Francisco, CA 94143 USA.
29
Division of Hematology/Oncology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455 USA.
30
Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana B106, Boston, MA 02215 USA.
31
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030 USA.
32
Swedish Cancer Institute, 1221 Madison Street, Suite 1020, Seattle, WA 98104 USA.
33
University of Pennsylvania, 3400 Civic Center Blvd, PCAM 12 South Pavilion, Philadelphia, PA 19104 USA.
34
Patients Against Lymphoma, 3774 Buckwampum Road, Riegelsville, PA 18077 USA.
35
Dana-Farber Cancer Institute, 450 Brookline Ave, Mayer 513, Boston, MA 02215 USA.
36
Hackensack University Medical Center, 92 2nd St., Hackensack, NJ 07601 USA.
37
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA.
38
University of California, Los Angeles, 10833 LeConte Ave., Los Angeles, CA 90095 USA.
39
University of Arkansas for Medical Sciences, Myeloma Institute, 4301 W Markham #816, Little Rock, AR 72205 USA.
40
Winship Cancer Institute, Emory University, 1365B Clifton Road NE, Atlanta, GA 30322 USA.
41
University of Pittsburgh Medical Center, 200 Lothrop St., Pittsburgh, PA 15213 USA.
42
Patient Advocate, 33 East Bellevue Place, Chicago, IL 60611 USA.
43
Cancer Research Foundation of New York, 43 Longview Lane, Chappaqua, NY 10514 USA.
44
Department of Hematology & Immunobiology, Yale University, 333 Cedar Street, Box 208021, New Haven, CT 06510 USA.
#
Contributed equally

Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

KEYWORDS:

Acute leukemia; Cancer immunotherapy; Hematologic malignancies; Immunotherapy; Lymphoma; Multiple myeloma

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center